Statins decrease bone turnover in postmenopausal women: a cross-sectional study

Background Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and some studies have shown a reduced occurrence of fractures in subjects on long‐term treatment with statins. We studied the effects of treatmen...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of clinical investigation Vol. 32; no. 8; pp. 581 - 589
Main Authors:	Rejnmark, L., Buus, N. H., Vestergaard, P., Andreasen, F., Larsen, M. L., Mosekilde, L.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Science Ltd 01-08-2002 Blackwell Publishing Ltd
Subjects:	Aged Alkaline Phosphatase - blood Biochemical bone markers Biomarkers - blood bone Bone Density Bone Remodeling - drug effects Calcium - metabolism Collagen - blood Collagen Type I Cross-Sectional Studies Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - drug therapy Hypercholesterolemia - metabolism Linear Models Middle Aged Osteocalcin - blood osteoporosis Parathyroid Hormone - blood Peptides - blood postmenopausal women Postmenopause - metabolism Simvastatin - therapeutic use statins
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Background Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and some studies have shown a reduced occurrence of fractures in subjects on long‐term treatment with statins. We studied the effects of treatment with statins on calcium homeostasis, bone turnover and bone mineral density. Design In a cross‐sectional design, plasma levels of parathyroid hormone (PTH) and biochemical markers of bone turnover, bone mineral density (BMD) and body composition (fat‐ and lean tissue‐mass) were measured in 140 postmenopausal women who had been treated with a statin for more than 2 years (median 4 years) and compared to 140 age‐ and gender‐matched, population‐based controls. Results Plasma levels of bone turnover markers were lower in the statin‐treated subjects than in the controls: osteocalcin (−9%, P = 0·03), bone‐specific alkaline phosphatase (−14%, P < 0·01), and C‐terminal telopeptide of type I collagen (−11%, P < 0·01). On the other hand, plasma PTH levels were 16% higher in the statin‐treated subjects than in the controls (P < 0·01). However, body composition and BMD at the lumbar spine, hip, forearm and whole body did not differ between the two groups. No correlation could be demonstrated between changes in biochemical quantities and dose or duration of statin use. Conclusion Our data show that statins affect the function of bone cells. Most likely, the effect is antiresorptive.
AbstractList	Background Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and some studies have shown a reduced occurrence of fractures in subjects on long‐term treatment with statins. We studied the effects of treatment with statins on calcium homeostasis, bone turnover and bone mineral density. Design In a cross‐sectional design, plasma levels of parathyroid hormone (PTH) and biochemical markers of bone turnover, bone mineral density (BMD) and body composition (fat‐ and lean tissue‐mass) were measured in 140 postmenopausal women who had been treated with a statin for more than 2 years (median 4 years) and compared to 140 age‐ and gender‐matched, population‐based controls. Results Plasma levels of bone turnover markers were lower in the statin‐treated subjects than in the controls: osteocalcin (−9%, P = 0·03), bone‐specific alkaline phosphatase (−14%, P < 0·01), and C‐terminal telopeptide of type I collagen (−11%, P < 0·01). On the other hand, plasma PTH levels were 16% higher in the statin‐treated subjects than in the controls ( P < 0·01). However, body composition and BMD at the lumbar spine, hip, forearm and whole body did not differ between the two groups. No correlation could be demonstrated between changes in biochemical quantities and dose or duration of statin use. Conclusion Our data show that statins affect the function of bone cells. Most likely, the effect is antiresorptive. Background Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and some studies have shown a reduced occurrence of fractures in subjects on long‐term treatment with statins. We studied the effects of treatment with statins on calcium homeostasis, bone turnover and bone mineral density. Design In a cross‐sectional design, plasma levels of parathyroid hormone (PTH) and biochemical markers of bone turnover, bone mineral density (BMD) and body composition (fat‐ and lean tissue‐mass) were measured in 140 postmenopausal women who had been treated with a statin for more than 2 years (median 4 years) and compared to 140 age‐ and gender‐matched, population‐based controls. Results Plasma levels of bone turnover markers were lower in the statin‐treated subjects than in the controls: osteocalcin (−9%, P = 0·03), bone‐specific alkaline phosphatase (−14%, P < 0·01), and C‐terminal telopeptide of type I collagen (−11%, P < 0·01). On the other hand, plasma PTH levels were 16% higher in the statin‐treated subjects than in the controls (P < 0·01). However, body composition and BMD at the lumbar spine, hip, forearm and whole body did not differ between the two groups. No correlation could be demonstrated between changes in biochemical quantities and dose or duration of statin use. Conclusion Our data show that statins affect the function of bone cells. Most likely, the effect is antiresorptive. BACKGROUNDStatins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and some studies have shown a reduced occurrence of fractures in subjects on long-term treatment with statins. We studied the effects of treatment with statins on calcium homeostasis, bone turnover and bone mineral density. DESIGNIn a cross-sectional design, plasma levels of parathyroid hormone (PTH) and biochemical markers of bone turnover, bone mineral density (BMD) and body composition (fat- and lean tissue-mass) were measured in 140 postmenopausal women who had been treated with a statin for more than 2 years (median 4 years) and compared to 140 age- and gender-matched, population-based controls. RESULTSPlasma levels of bone turnover markers were lower in the statin-treated subjects than in the controls: osteocalcin (-9%, P = 0.03), bone-specific alkaline phosphatase (-14%, P < 0.01), and C-terminal telopeptide of type I collagen (-11%, P < 0.01). On the other hand, plasma PTH levels were 16% higher in the statin-treated subjects than in the controls (P < 0.01). However, body composition and BMD at the lumbar spine, hip, forearm and whole body did not differ between the two groups. No correlation could be demonstrated between changes in biochemical quantities and dose or duration of statin use. CONCLUSIONOur data show that statins affect the function of bone cells. Most likely, the effect is antiresorptive. Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and some studies have shown a reduced occurrence of fractures in subjects on long-term treatment with statins. We studied the effects of treatment with statins on calcium homeostasis, bone turnover and bone mineral density. In a cross-sectional design, plasma levels of parathyroid hormone (PTH) and biochemical markers of bone turnover, bone mineral density (BMD) and body composition (fat- and lean tissue-mass) were measured in 140 postmenopausal women who had been treated with a statin for more than 2 years (median 4 years) and compared to 140 age- and gender-matched, population-based controls. Plasma levels of bone turnover markers were lower in the statin-treated subjects than in the controls: osteocalcin (-9%, P = 0.03), bone-specific alkaline phosphatase (-14%, P < 0.01), and C-terminal telopeptide of type I collagen (-11%, P < 0.01). On the other hand, plasma PTH levels were 16% higher in the statin-treated subjects than in the controls (P < 0.01). However, body composition and BMD at the lumbar spine, hip, forearm and whole body did not differ between the two groups. No correlation could be demonstrated between changes in biochemical quantities and dose or duration of statin use. Our data show that statins affect the function of bone cells. Most likely, the effect is antiresorptive.
Author	Buus, N. H. Vestergaard, P. Rejnmark, L. Larsen, M. L. Mosekilde, L. Andreasen, F.
Author_xml	– sequence: 1 givenname: L. surname: Rejnmark fullname: Rejnmark, L. email: rejnmark@post6.tele.dk organization: Aarhus University Hospital – sequence: 2 givenname: N. H. surname: Buus fullname: Buus, N. H. organization: Aarhus University Hospital – sequence: 3 givenname: P. surname: Vestergaard fullname: Vestergaard, P. organization: Aarhus University Hospital – sequence: 4 givenname: F. surname: Andreasen fullname: Andreasen, F. organization: Aarhus University, Aarhus, Denmark – sequence: 5 givenname: M. L. surname: Larsen fullname: Larsen, M. L. organization: Aarhus University Hospital – sequence: 6 givenname: L. surname: Mosekilde fullname: Mosekilde, L. organization: Aarhus University Hospital
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/12190958$$D View this record in MEDLINE/PubMed
BookMark	eNqNkE1r3DAQhkVJaTZp_0IROeRmdyRZlhXIISxJGggN9IP2JmR5DN56rY1kJ7v_vnJ2SaGnniQxzzujeU7I0eAHJIQyyBkU5adVzkQpMy5KnnMAngMDXuTbN2TxWjgiCwBWZFwrfkxOYlwBQMUEf0eOGWcatKwW5OHbaMduiLRBF9BGpHUaRccpDP4JA-0GuvFxXOPgN3aKtqfPPj0uqKUu-BiziG7s_JAKcZya3XvytrV9xA-H85T8uLn-vvyc3T_c3i2v7jMni7LIVCuc1Ay5dg0T0DSirYVlTmDlpOJSaCW44nXDqtJpqFWpK8krhs7W3LpWnJLzfd9N8I8TxtGsu-iw7-2AfopG8SSkAkjg2T_gyqfl0t8M05qlIVokqNpDLzsFbM0mdGsbdoaBmY2blZnFmlmsmY2bF-Nmm6IfD_2neo3N3-BBcQIu98Bz1-Puvxub6-XdfEv5bJ_v4ojb17wNv02phJLm55db80uB_MqXzJTiD9Sdn0U
CitedBy_id	crossref_primary_10_1007_s00198_004_1793_0 crossref_primary_10_1016_j_metabol_2014_07_011 crossref_primary_10_1111_j_1365_2362_2009_02092_x crossref_primary_10_1161_ATVBAHA_120_315737 crossref_primary_10_1093_nsr_nwu028 crossref_primary_10_1097_00000441_200608000_00001 crossref_primary_10_1161_CIRCULATIONAHA_109_912774 crossref_primary_10_1007_s00223_006_0024_4 crossref_primary_10_1016_j_archger_2014_07_006 crossref_primary_10_1007_s00198_005_1897_1 crossref_primary_10_1093_ejo_cjy048 crossref_primary_10_1165_rcmb_2003_0267OC crossref_primary_10_1016_j_ultrasmedbio_2008_11_003 crossref_primary_10_1507_endocrj_K06_127 crossref_primary_10_1007_s10067_004_1053_x crossref_primary_10_1093_ejo_cjy001 crossref_primary_10_1177_001857870203701202 crossref_primary_10_1359_JBMR_040607 crossref_primary_10_3346_jkms_2005_20_3_438 crossref_primary_10_3928_0147_7447_20050101_15 crossref_primary_10_1016_j_bone_2007_02_019 crossref_primary_10_1097_01_TA_0000240974_07999_bc crossref_primary_10_1592_phco_25_2_228_56954 crossref_primary_10_1016_j_phrs_2013_12_009 crossref_primary_10_1517_13543784_17_10_1435 crossref_primary_10_1211_jpp_58_1_0002 crossref_primary_10_1016_j_bonr_2021_101152 crossref_primary_10_1016_j_ejphar_2012_01_014 crossref_primary_10_2169_internalmedicine_46_0419 crossref_primary_10_1046_j_1365_2362_2002_01025_x crossref_primary_10_1155_2010_957174 crossref_primary_10_2217_14750708_4_4_407 crossref_primary_10_1111_j_1527_3458_2004_tb00009_x crossref_primary_10_1097_ID_0b013e3182611ff6 crossref_primary_10_1007_s10557_009_6181_8 crossref_primary_10_1002_pds_984 crossref_primary_10_1016_j_bcp_2004_08_036 crossref_primary_10_1016_j_metabol_2004_01_010 crossref_primary_10_1016_j_mehy_2006_05_009 crossref_primary_10_5387_fms_57_19 crossref_primary_10_1016_j_cca_2014_06_028 crossref_primary_10_1507_endocrj_K07E_004 crossref_primary_10_1359_jbmr_040209 crossref_primary_10_3390_jcdd11020060 crossref_primary_10_4158_EP_13_6_620
Cites_doi	10.1001/jama.283.24.3211 10.1359/jbmr.1998.13.4.581 10.1056/NEJM199908123410707 10.1210/jc.85.3.1137 10.1210/jc.76.6.1399 10.1016/S0140-6736(00)04042-3 10.1002/jbmr.5650101008 10.1093/oxfordjournals.aje.a116954 10.1001/jama.283.24.3205 10.1001/jama.285.14.1850 10.1016/S0140-6736(00)02408-9 10.1093/clinchem/41.10.1439 10.1126/science.286.5446.1946 10.1161/hq1001.097781 10.1001/jama.284.15.1921 10.1093/clinchem/45.7.1009 10.1007/s001980070062 10.1359/jbmr.2000.15.3.599
ContentType	Journal Article
Copyright	Copyright Blackwell Scientific Publications Ltd. Aug 2002
Copyright_xml	– notice: Copyright Blackwell Scientific Publications Ltd. Aug 2002
DBID	BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7U7 7U9 8FD C1K FR3 H94 P64 7X8
DOI	10.1046/j.1365-2362.2002.01024.x
DatabaseName	Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts AIDS and Cancer Research Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1365-2362
EndPage	589
ExternalDocumentID	202305641 10_1046_j_1365_2362_2002_01024_x 12190958 ECI1024 ark_67375_WNG_X705R2C1_6
Genre	article Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7QO 7U7 7U9 8FD C1K FR3 H94 P64 7X8
ID	FETCH-LOGICAL-c5464-7f3c591e29cd130dd3fb3a1c3e8c57253973272bd186c90b76985281ecab2acf3
IEDL.DBID	33P
ISSN	0014-2972
IngestDate	Fri Aug 16 08:47:39 EDT 2024 Thu Oct 10 22:03:44 EDT 2024 Thu Nov 21 20:40:45 EST 2024 Sat Sep 28 08:40:17 EDT 2024 Sat Aug 24 00:55:08 EDT 2024 Wed Oct 30 09:53:35 EDT 2024
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	8
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c5464-7f3c591e29cd130dd3fb3a1c3e8c57253973272bd186c90b76985281ecab2acf3
Notes	ArticleID:ECI1024 istex:98F66E7EBD782A2C96629FE57CBBDF2FF8B67FF3 ark:/67375/WNG-X705R2C1-6 Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus University Hospital (L. Rejnmark, N. H. Buus, P. Vestergaard, L. Mosekilde); Centre for Clinical Pharmacology, Faculty of Health Sciences, Aarhus University (L. Rejnmark, N. H. Buus, F. Andreasen); Department of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus University Hospital (M. L. Larsen); Faculty of Health Sciences, Aarhus University (P. Vestergaard, L. Mosekilde); Aarhus, DenmarkAarhus, Denmark. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2362.2002.01024.x
PMID	12190958
PQID	199127293
PQPubID	36545
PageCount	9
ParticipantIDs	proquest_miscellaneous_72024800 proquest_journals_199127293 crossref_primary_10_1046_j_1365_2362_2002_01024_x pubmed_primary_12190958 wiley_primary_10_1046_j_1365_2362_2002_01024_x_ECI1024 istex_primary_ark_67375_WNG_X705R2C1_6
PublicationCentury	2000
PublicationDate	August 2002
PublicationDateYYYYMMDD	2002-08-01
PublicationDate_xml	– month: 08 year: 2002 text: August 2002
PublicationDecade	2000
PublicationPlace	Oxford, UK
PublicationPlace_xml	– name: Oxford, UK – name: England – name: Oxford
PublicationTitle	European journal of clinical investigation
PublicationTitleAlternate	Eur J Clin Invest
PublicationYear	2002
Publisher	Blackwell Science Ltd Blackwell Publishing Ltd
Publisher_xml	– name: Blackwell Science Ltd – name: Blackwell Publishing Ltd
References	Morton DJ, Barrett Connor EL, Edelstein SL. Thiazides and bone mineral density in elderly men and women. Am J Epidemiol 1994;139: 1107-15. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001;21: 1636-41. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13: 581-9. Reid IR, Hague W, Emberson J, Baker J, Tonkin A et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001;357: 509-12. Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995;41: 1439-45. Van Staa TP, Wegman S, De Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001;285: 1850-5. Greenspan SL, Holland S, Maitland RL, Poku M, Freeman A, Yuan W et al. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians 1996;108: 230-8. Wasnich RD, Ross PD, Heilbrun LK, Vogel JM, Yano K, Benfante RJ. Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence. Obstet Gynecol 1986;67: 457-62. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000;85: 1137-42. Kress BC, Mizrahi IA, Armour KW, Marcus R, Emkey RD, Santora AC. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Clin Chem 1999;45: 1009-17. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000;15: 599-604. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993;76: 1399-406. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000;11: 637-59. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10: 1478-87. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone mineral density in postmenopausal women. Lancet 2000;355: 2218-19. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341: 498-511. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283: 3211-16. Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture: 4s Study Group. JAMA 2000;284: 1921-2. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283: 3205-10. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286: 1946-9. 1995; 41 1994; 139 2001; 285 2000; 355 2000; 15 1986; 67 1993; 76 2000; 11 2000; 85 1995; 10 1999; 341 1999; 286 1999; 45 2000; 283 2000; 284 2001; 357 1996; 108 1998; 13 2001; 21 12190951 - Eur J Clin Invest. 2002 Aug;32(8):543-4 e_1_2_6_20_2 Kress BC (e_1_2_6_17_2) 1999; 45 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_18_2 Wasnich RD (e_1_2_6_19_2) 1986; 67 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_2_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_21_2 e_1_2_6_16_2 Greenspan SL (e_1_2_6_15_2) 1996; 108 e_1_2_6_14_2
References_xml	– volume: 341 start-page: 498 year: 1999 end-page: 511 article-title: Drug treatment of lipid disorders publication-title: N Engl J Med – volume: 41 start-page: 1439 year: 1995 end-page: 45 article-title: Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies publication-title: Clin Chem – volume: 108 start-page: 230 year: 1996 end-page: 8 article-title: Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy publication-title: Proc Assoc Am Physicians – volume: 283 start-page: 3205 year: 2000 end-page: 10 article-title: HMG‐CoA reductase inhibitors and the risk of fractures publication-title: JAMA – volume: 45 start-page: 1009 year: 1999 end-page: 17 article-title: Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women publication-title: Clin Chem – volume: 21 start-page: 1636 year: 2001 end-page: 41 article-title: Effect of statins on bone mineral density and bone histomorphometry in rodents publication-title: Arterioscler Thromb Vasc Biol – volume: 286 start-page: 1946 year: 1999 end-page: 9 article-title: Stimulation of bone formation in vitro and in rodents by statins publication-title: Science – volume: 355 start-page: 2218 year: 2000 end-page: 19 article-title: Oral statins and increased bone mineral density in postmenopausal women publication-title: Lancet – volume: 13 start-page: 581 year: 1998 end-page: 9 article-title: Nitrogen‐containing bisphosphonates inhibit the mevalonate pathway and prevent post‐translational prenylation of GTP‐binding proteins, including Ras publication-title: J Bone Miner Res – volume: 283 start-page: 3211 year: 2000 end-page: 16 article-title: HMG‐CoA reductase inhibitors and the risk of hip fractures in elderly patients publication-title: JAMA – volume: 10 start-page: 1478 year: 1995 end-page: 87 article-title: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo publication-title: J Bone Miner Res – volume: 285 start-page: 1850 year: 2001 end-page: 5 article-title: Use of statins and risk of fractures publication-title: JAMA – volume: 284 start-page: 1921 year: 2000 end-page: 2 article-title: Statin drugs and the risk of fracture: 4s Study Group publication-title: JAMA – volume: 357 start-page: 509 year: 2001 end-page: 12 article-title: Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long‐term Intervention with Pravastatin in Ischaemic Disease publication-title: Lancet – volume: 76 start-page: 1399 year: 1993 end-page: 406 article-title: The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women publication-title: J Clin Endocrinol Metab – volume: 11 start-page: 637 year: 2000 end-page: 59 article-title: Drug‐induced bone loss publication-title: Osteoporos Int – volume: 67 start-page: 457 year: 1986 end-page: 62 article-title: Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence publication-title: Obstet Gynecol – volume: 139 start-page: 1107 year: 1994 end-page: 15 article-title: Thiazides and bone mineral density in elderly men and women publication-title: Am J Epidemiol – volume: 85 start-page: 1137 year: 2000 end-page: 42 article-title: HMG‐CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients publication-title: J Clin Endocrinol Metab – volume: 15 start-page: 599 year: 2000 end-page: 604 article-title: Chronic intravenous aminobisphosphonate therapy increases high‐density lipoprotein cholesterol and decreases low‐density lipoprotein cholesterol publication-title: J Bone Miner Res – ident: e_1_2_6_8_2 doi: 10.1001/jama.283.24.3211 – ident: e_1_2_6_3_2 doi: 10.1359/jbmr.1998.13.4.581 – ident: e_1_2_6_2_2 doi: 10.1056/NEJM199908123410707 – ident: e_1_2_6_13_2 doi: 10.1210/jc.85.3.1137 – ident: e_1_2_6_16_2 doi: 10.1210/jc.76.6.1399 – ident: e_1_2_6_11_2 doi: 10.1016/S0140-6736(00)04042-3 – ident: e_1_2_6_4_2 doi: 10.1002/jbmr.5650101008 – ident: e_1_2_6_20_2 doi: 10.1093/oxfordjournals.aje.a116954 – volume: 108 start-page: 230 year: 1996 ident: e_1_2_6_15_2 article-title: Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy publication-title: Proc Assoc Am Physicians contributor: fullname: Greenspan SL – ident: e_1_2_6_7_2 doi: 10.1001/jama.283.24.3205 – ident: e_1_2_6_9_2 doi: 10.1001/jama.285.14.1850 – ident: e_1_2_6_12_2 doi: 10.1016/S0140-6736(00)02408-9 – ident: e_1_2_6_14_2 doi: 10.1093/clinchem/41.10.1439 – ident: e_1_2_6_5_2 doi: 10.1126/science.286.5446.1946 – ident: e_1_2_6_6_2 doi: 10.1161/hq1001.097781 – ident: e_1_2_6_10_2 doi: 10.1001/jama.284.15.1921 – volume: 67 start-page: 457 year: 1986 ident: e_1_2_6_19_2 article-title: Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence publication-title: Obstet Gynecol contributor: fullname: Wasnich RD – volume: 45 start-page: 1009 year: 1999 ident: e_1_2_6_17_2 article-title: Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women publication-title: Clin Chem doi: 10.1093/clinchem/45.7.1009 contributor: fullname: Kress BC – ident: e_1_2_6_21_2 doi: 10.1007/s001980070062 – ident: e_1_2_6_18_2 doi: 10.1359/jbmr.2000.15.3.599
SSID	ssj0008132
Score	1.98118
Snippet	Background Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and... Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and some... Background Statins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and... BACKGROUNDStatins have been suggested as potential agents in the management of osteoporosis. Reviews of medical records have shown an increased bone mass and...
SourceID	proquest crossref pubmed wiley istex
SourceType	Aggregation Database Index Database Publisher
StartPage	581
SubjectTerms	Aged Alkaline Phosphatase - blood Biochemical bone markers Biomarkers - blood bone Bone Density Bone Remodeling - drug effects Calcium - metabolism Collagen - blood Collagen Type I Cross-Sectional Studies Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - drug therapy Hypercholesterolemia - metabolism Linear Models Middle Aged Osteocalcin - blood osteoporosis Parathyroid Hormone - blood Peptides - blood postmenopausal women Postmenopause - metabolism Simvastatin - therapeutic use statins
Title	Statins decrease bone turnover in postmenopausal women: a cross-sectional study
URI	https://api.istex.fr/ark:/67375/WNG-X705R2C1-6/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2362.2002.01024.x https://www.ncbi.nlm.nih.gov/pubmed/12190958 https://www.proquest.com/docview/199127293 https://search.proquest.com/docview/72024800
Volume	32
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9VAFD5oBXGj9R3rIwtxl5LMTDIz3ZXrrVWw-MTuhnlCEXJL44Uu_Qn-Rn-Jc06SWwpdiLgLhEzOnMl5TM433wF4qX10ylldJelcJXxIldNJV8EnZ-vEraJmMIef5dGxer1Empx381mYkR9i88MNLYP8NRq4dWMXkprYbWeEVvbAhDTYRXY0sYv5ZN400GkO_mHjlFXDR-LwRlRMyxnUMxU4rxzoUqS6gUo_vyoNvZzVUlg6uPM_J7QNt6fktNwfv6a7cC329-Dm-6n8fh8-Ymp60g9loGRziKVb9bHMUatHJGh50penqwFx63krvh7yUETwsFfakub4--evgaBf-BYitn0AXw-WXxaH1dSTofKt6EQlE_etbiLTPuTwFwJPjtvG86h8K1nLkf1HMhca1XldO9lp1TLVRG8dsz7xh7DVZ9EeQ5lzLYVk9t45Kbz1qo5JtVIkH7VgNhTQzPo3pyP1hqGSucDjZagrg7rCRprMkK7MeQGvaKE2D9iz7whdk635dvTGHMu6_cQWjekK2JlX0kxWOxiEgWXhNS_gxeZuNjesodg-rtaDkQxJ4Oq6gEfj8l-Iln1_zldVAR2t8l_LbJaLt3j15F8f3IFb1KOGYIlPYevH2To-g-tDWD8nI_gDmeMDww
link.rule.ids	315,782,786,1408,27933,27934,46064,46488
linkProvider	Wiley-Blackwell
linkToHtml	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB61ILVc6BtS2uJD1VsgsZPY7q3aLl0ErFpKBTfLTwlVyiLCShz5Cf2N_SX1ONlFSByqqrdIkR17xvOI5_NngPfSeiOMlnngxuSVdSE3Msjc2WB0EZgW6TKYyXc-PROfx0iTc7A4C9PzQyw33NAykr9GA8cN6d2hLNlbeYJoRRecoAY7SI9W7cSEcrVq4rrE8xzs69Iti5L11OFllVPJF7CeocR5b093YtUqiv36vkT0bl6bAtPek_86paewPuSn5FO_oJ7BA98-h0dHQwX-BXzD7PS87YhL-WbniZm1nsTA1SIYlJy35GLWIXQ9_o3Pu9hV4nj4SDRJk_x986tL6C_8SuK2fQk_9sYno0k-XMuQ2zoKNueB2VqWnkrrYgR0jgXDdGmZF7bmtGZIAMSpcaVorCwMb6SoqSi91YZqG9grWGnj0DaBxHRLIJ-9NYZXVltR-CBqXgXrZUW1y6BcKEBd9OwbKlXNKzxhhrJSKCu8S5OqJCt1ncGHpKllA335E9FrvFan0y_qjBf1MR2Vqslga6FKNRhupxAJFgcvWQbby7fR4rCMols_m3eKU-SBK4oMNnr93w4tuv-YsooMmqTmvx6zGo_28en1vzbchseTk6NDdbg_PdiCtXRlTUIpvoGVq8u5fwsPOzd_lyziDxfQB-s
linkToPdf	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BK1VceFNCgfqAuKUkthPb3NB2l5bHqrxEb5afUoWUXTWs1CM_gd_IL8HjZBdV6gEhbpEiO_ZMZvwl8_kzwDPlgpXWqDIKa0vufCytiqr0LlpTRWZkPgzm6JOYn8rDKcrkvFnvhRn0ITY_3DAycr7GAF_6-GKsSg5BnhlaKQNnpsEBqqPxg4Qnt3lC5aijz9jJJivLmg3K4TUvqRJrVs9Y4byyp0tL1TZa_eIqHHoZ1uZ1aXbrf87oNtwc0Sl5NbxOd-Ba6O7Czvux_n4PPiA2Pet64jPa7AOxiy6QtGx1SAUlZx1ZLnokrqdv8VWfusoKDy-JIXmOv3787DP3C5-SlW3vw5fZ9PPkqBwPZShdw1teishco-pAlfNp_fOeRctM7ViQrhG0YSj_I6j1tWydqqxolWyorIMzlhoX2QPY6tLQHgJJYEuimr2zVnBnnKxClI3g0QXFqfEF1Gv76-WgvaFzzZzj_jK0lUZb4UmaVGdb6YsCnmdHbRqY82_IXRON_jp_rU9F1Xykk1q3BeytPanHsO018sDS4BUrYH9zN8UbFlFMFxarXguKKnBVVcDu4P4_Q0vJPwFWWUCbvfzXY9bTyTFePfrXhvuwc3I40--O52_34EY-ryZTFB_D1vfzVXgC13u_eprj4TfGugaR
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Statins+decrease+bone+turnover+in+postmenopausal+women%3A+a+cross%E2%80%90sectional+study&rft.jtitle=European+journal+of+clinical+investigation&rft.au=Rejnmark%2C+L.&rft.au=Buus%2C+N.+H.&rft.au=Vestergaard%2C+P.&rft.au=Andreasen%2C+F.&rft.date=2002-08-01&rft.pub=Blackwell+Science+Ltd&rft.issn=0014-2972&rft.eissn=1365-2362&rft.volume=32&rft.issue=8&rft.spage=581&rft.epage=589&rft_id=info:doi/10.1046%2Fj.1365-2362.2002.01024.x&rft.externalDBID=10.1046%252Fj.1365-2362.2002.01024.x&rft.externalDocID=ECI1024
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2972&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2972&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2972&client=summon